Previous close | 39.23 |
Open | 39.31 |
Bid | 39.36 x 800 |
Ask | 45.69 x 800 |
Day's range | 39.03 - 39.56 |
52-week range | 34.74 - 47.70 |
Volume | |
Avg. volume | 1,060,685 |
Market cap | 8.737B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 25.80 |
EPS (TTM) | 1.53 |
Earnings date | 29 Apr 2024 |
Forward dividend & yield | 1.28 (2.94%) |
Ex-dividend date | 30 Jan 2024 |
1y target est | 50.99 |
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - C
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows targeted next-generation sequencing of T-cell receptors, increasing accuracy and sensitivity PAXgene® Urine Liquid Biopsy Set to enable non-invasive sample collection and cell-free DNA stabilization, thereby allowing researchers to make advances in urine liquid biopsyVenlo, the Ne